NEW YORK – Beijing-based precision oncology firm Genetron Health expects to see significant progress this year in the commercial rollout of its blood-based liver cancer screening test, HCCScreen, as well as in various research efforts intended to support new regulatory submissions.
The company also expects it will expand its core early detection technology across additional cancer types.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
